Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Aug;49(10):3332-3333.
doi: 10.1007/s00259-022-05833-6. Epub 2022 May 6.

[177Lu]Lu-DOTATATE peptide receptor radionuclide therapy-associated myeloid neoplasms: insights from the WHO pharmacovigilance database

Jonathan Vigne  1   2   3 , Basile Chrétien  4 , Anne-Laure Bignon  5 , Karine Bouhier-Leporrier  5 , Charles Dolladille  6
Affiliations

[177Lu]Lu-DOTATATE peptide receptor radionuclide therapy-associated myeloid neoplasms: insights from the WHO pharmacovigilance database

Jonathan Vigne et al. Eur J Nucl Med Mol Imaging. 2022 Aug.
No abstract available

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752–63. https://doi.org/10.1016/S1470-2045(21)00572-6 . - DOI - PubMed
    1. Goncalves I, Burbury K, Michael M, Iravani A, Ravi Kumar AS, Akhurst T, et al. Characteristics and outcomes of therapy-related myeloid neoplasms after peptide receptor radionuclide/chemoradionuclide therapy (PRRT/PRCRT) for metastatic neuroendocrine neoplasia: a single-institution series. Eur J Nucl Med Mol Imaging. 2019;46:1902–10. https://doi.org/10.1007/s00259-019-04389-2 . - DOI - PubMed
    1. Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376:125–35. https://doi.org/10.1056/NEJMoa1607427 . - DOI - PubMed - PMC
    1. van der Zwan WA, Brabander T, Kam BLR, Teunissen JJM, Feelders RA, Hofland J, et al. Salvage peptide receptor radionuclide therapy with [177Lu-DOTA, Tyr3]octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2019;46:704–17. https://doi.org/10.1007/s00259-018-4158-1 . - DOI - PubMed

LinkOut - more resources